RxDoctor Payments Data

Erica Kasper, MD

Infectious Disease · Fresno, CANPI 1912160896

Payments from drug & device makers

$24,337in general payments, 2019–2025

Across 63 payments — averaging $386.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$24K
  • AbbVie$25
  • Viiv Healthcare Company$15

What the payments were for

  • Consulting fees$9004%
  • Speaking & faculty fees$18,76077%
  • Travel & lodging$3,46314%
  • Food & beverage$1,2145%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead61$24,297
AbbVie1$25
Viiv Healthcare Company1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,337 in reported general payments places this provider in the 80th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$5,379
Medicare patients
29
Services billed
62

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala290$1,169,417
TriumeqAbacavir/Dolutegravir/Lamivudi58$256,666
GenvoyaElviteg/Cob/Emtri/Tenof Alafen43$191,854
TivicayDolutegravir Sodium53$117,641
DescovyEmtricitabine/Tenofov Alafenam45$109,600
JulucaDolutegravir/Rilpivirine24$87,208
PrezcobixDarunavir/Cobicistat27$82,013
OdefseyEmtricitab/Rilpiviri/Tenof Ala15$52,735
VemlidyTenofovir Alafenamide12$19,726
Darunavir18$8,876
TradjentaLinagliptin11$4,900
Fluconazole21$2,186
Albuterol Sulfate HfaAlbuterol Sulfate42$1,078
Ritonavir18$1,018
Atorvastatin Calcium102$513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy, Vemlidy$24,297$1,490,598390 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Juluca$15$461,515135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 856 infectious disease providers in California.

Other infectious disease in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →